Reforgene named among China's Top 100 Innovative Pharmaceutical Companies 2026

Recently, the 2026 China Pharmaceutical Innovation 100 conference hosted by E Pharmacy Manager concluded successfully. The conference officially released the authoritative list of "2026 China Top 100 Innovative Pharmaceutical Enterprises", and Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") was successfully listed, joining the ranks of China's Top 100 innovative pharmaceutical enterprises for 2026.

This edition of the 2026 China Pharmaceutical Innovation 100 conference brought together leading figures from government, industry, academia, research, investment and clinical fields, focusing on frontier hotspots such as CGT cell and gene therapy, nucleic acid medicines, clinical development of new drugs and the globalization of biomedicine, to jointly discuss the path of high-quality development of China's innovative drug industry. Relying on professional big data and a quantitative evaluation system, the list is a core wind vane for judging the innovation hard power of domestic biomedical enterprises.

As a leading innovative gene editing drug company in China, Reforgene takes gene editing technology as its core and is dedicated to bringing novel medicines to life. Relying on continuously increasing R&D investment and a leading gene editing drug platform, it has accumulated pioneering achievements in multiple drug directions including hematology, cardiovascular, metabolic and infectious diseases. In hematology, Reforgene has completed the confirmatory clinical trial of its beta-thalassemia product RM001, with all subjects maintaining transfusion independence and excellent clinical data achieved. Its alpha-thalassemia product RM004 has conducted the world's first human trial for this disease and successfully cured the first patient. Reforgene's ophthalmology product for Usher syndrome has obtained clinical approval in both China and the United States, the world's first medicine of its kind for this indication. At present, Reforgene's gene editing therapies for chronic diseases are accelerating into the clinical stage.

This selection is high recognition by the industry of Reforgene's comprehensive strength in technological innovation, drug R&D and industrialization potential. Thanks to the long-term accumulation of underlying gene editing technology and R&D platforms, Reforgene is entering a new development stage of scaled pipeline advancement and global value realization.